A widely publicised Cochrane review published on April 16, 2026, set out to synthesise evidence on the efficacy and safety of amyloid β-targeting monoclonal antibodies for Alzheimer's disease.1 The ...
US scientists have built a high-throughput biological platform that could speed up the search ...